Literature DB >> 16770643

Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3'-oxime from molecular dynamics simulations.

Bing Zhang1, Vincent B C Tan, Kian Meng Lim, Tong Earn Tay, Shulin Zhuang.   

Abstract

Molecular dynamics simulations were performed to elucidate the interactions of CDK2 and CDK5 complexes with three inhibitors: R-roscovitine, S-roscovitine, and indirubin-3'-oxime. The preference of the two complexes for R-roscovitine over the S enantiomer, as reported by the experiment, was also found by the simulations. More importantly, the simulations showed that the cause of the stronger affinity for the R enantiomer is the presence of an important hydrogen bond between R-roscovitine and the kinases not found with S-roscovitine. The simulations also showed two amino acid mutations in the active site of CDK5/R-roscovitine that favor binding-enhanced electrostatic contributions, making the inhibitor more effective for CDK5 than for CDK2. This suggests that the effectiveness of roscovitine-like inhibitors can be improved by enhancing their electrostatic interaction with the kinases. Finally, molecular mechanics-Possion-Boltzmann/surface area calculations of the CDK5/indirubin-3'-oxime system in both water-excluded and water-included environments gave significantly different electrostatic contributions to the binding. The simulations detected the displacement of a water molecule in the active site of the water-included CDK/indirubin-3'-oxime system. This resulted in a more conserved binding pattern than the water-excluded structure. Hence, in the design of new indirubin-like inhibitors, it is important to include the water molecule in the analysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16770643     DOI: 10.1007/s00894-006-0127-x

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  39 in total

Review 1.  Small molecules as inhibitors of cyclin-dependent kinases.

Authors:  Axel Huwe; Ralph Mazitschek; Athanassios Giannis
Journal:  Angew Chem Int Ed Engl       Date:  2003-05-16       Impact factor: 15.336

2.  Density functional study of the enzymatic reaction catalyzed by a cyclin-dependent kinase.

Authors:  Andrea Cavalli; Marco De Vivo; Maurizio Recanatini
Journal:  Chem Commun (Camb)       Date:  2003-06-07       Impact factor: 6.222

3.  Interaction of amiloride and one of its derivatives with Vpu from HIV-1: a molecular dynamics simulation.

Authors:  V Lemaitre; R Ali; C G Kim; A Watts; W B Fischer
Journal:  FEBS Lett       Date:  2004-04-09       Impact factor: 4.124

Review 4.  Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.

Authors:  M E Noble; J A Endicott
Journal:  Pharmacol Ther       Date:  1999 May-Jun       Impact factor: 12.310

Review 5.  Hydrogen bonding in globular proteins.

Authors:  E N Baker; R E Hubbard
Journal:  Prog Biophys Mol Biol       Date:  1984       Impact factor: 3.667

6.  Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.

Authors:  R Hoessel; S Leclerc; J A Endicott; M E Nobel; A Lawrie; P Tunnah; M Leost; E Damiens; D Marie; D Marko; E Niederberger; W Tang; G Eisenbrand; L Meijer
Journal:  Nat Cell Biol       Date:  1999-05       Impact factor: 28.824

7.  Molecular model of cyclin-dependent kinase 5 complexed with roscovitine.

Authors:  Walter Filgueira de Azevedo; Renato Tadeu Gaspar; Fernanda Canduri; João Carlos Camera; Nelson José Freitas da Silveira
Journal:  Biochem Biophys Res Commun       Date:  2002-10-11       Impact factor: 3.575

8.  Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.

Authors:  Hwangseo Park; Min Sun Yeom; Sangyoub Lee
Journal:  Chembiochem       Date:  2004-12-03       Impact factor: 3.164

Review 9.  Cyclin-dependent kinase 5 in amyotrophic lateral sclerosis.

Authors:  Minh Dang Nguyen; Jean-Pierre Julien
Journal:  Neurosignals       Date:  2003 Sep-Oct

Review 10.  Role of cdk5 in the pathogenesis of Alzheimer's disease.

Authors:  Lit-Fui Lau; Michael K Ahlijanian
Journal:  Neurosignals       Date:  2003 Sep-Oct
View more
  5 in total

1.  Mechanism of CDK5 activation revealed by steered molecular dynamics simulations and energy calculations.

Authors:  Bing Zhang; Zhou Cheng Su; Tong Earn Tay; Vincent B C Tan
Journal:  J Mol Model       Date:  2009-12-15       Impact factor: 1.810

2.  Regulation of Kalirin by Cdk5.

Authors:  Xiaonan Xin; Yanping Wang; Xin-ming Ma; Panteleimon Rompolas; Henry T Keutmann; Richard E Mains; Betty A Eipper
Journal:  J Cell Sci       Date:  2008-07-15       Impact factor: 5.285

3.  Explaining the inhibition of cyclin-dependent kinase 5 by peptides derived from p25 with molecular dynamics simulations and MM-PBSA.

Authors:  Vincent B C Tan; Bing Zhang; Kian Meng Lim; Tong Earn Tay
Journal:  J Mol Model       Date:  2009-05-23       Impact factor: 1.810

4.  Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design.

Authors:  Soumya Lipsa Rath; Sanjib Senapati
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

5.  Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.

Authors:  B K Binukumar; Varsha Shukla; Niranjana D Amin; Manju Bhaskar; Suzanne Skuntz; Joseph Steiner; Dirk Winkler; Steven L Pelech; Harish C Pant
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.